In Brief: Sonus' Echogen
Executive Summary
Sonus' Echogen: Medical Imaging Drugs Advisory Committee is scheduled to meet on June 30 to review the EchoGen Emulsion NDA for endocardial border delineation and left ventricular opacification in patients undergoing echocardiography and abdominal ultrasound for contrast enhancement and anatomic visualization in liver, kidney and peripheral vessels. The Bothell, Wash.-based company filed the NDA on Aug. 10, 1996...
Sonus' Echogen: Medical Imaging Drugs Advisory Committee is scheduled to meet on June 30 to review the EchoGen Emulsion NDA for endocardial border delineation and left ventricular opacification in patients undergoing echocardiography and abdominal ultrasound for contrast enhancement and anatomic visualization in liver, kidney and peripheral vessels. The Bothell, Wash.-based company filed the NDA on Aug. 10, 1996.... |